Skip to main content

Table 1 Main baseline features of the patients enrolled in the study

From: Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy

Patient Age Sex Primary tumour Metastases Previous therapy
1 76 M Ileum NET Liver Octreotide, interferon alfa
2 62 M Meningioma None None
3 61 M Pancreatic NET Local vessel infiltration Stenting
4 82 F Pancreatic NET Liver, bone Surgery
5 50 M Rectal NET Bone Surgery
6 67 F Liver NET LN, muscle, brain Surgery
7 69 M Small bowel NET Liver, lung, LN None
8 50 F Pancreatic NET Liver, LN Octreotide, everolimus, lanreotide
9 49 M Small cell lung cancer LN CTx
10 73 F Pancreatic NET Bone, liver Surgery
11 58 F Ileum NET Liver, LN Surgery, octreotide, thermoablation
12 57 F Carcinoid Lung, bone Surgery, RCTx
13 31 F Medullary thyroid cancer Lung, LN, bone Surgery, CTx
14 24 M Ileum NET Liver Surgery, TACE, octreotide
15 66 M Thymus NET Bone, lung, LN None
16 60 F Meningioma None Surgery
17 34 M Paraganglioma Bone Surgery, RTx
18 61 M Small bowel NET Liver, LN Surgery, octreotide
19 55 M Pancreatic NET Liver, LN CTx
20 63 M Pancreatic NET LN, liver, bone Surgery
21 68 F Small bowel NET Liver, LN Surgery
22 54 M Cerebral NET Bone CTx
  1. M male, F female, NET neuroendocrine tumour, LN lymph nodes, CTx chemotherapy, RCTx radiochemotherapy, TACE transcatheter arterial chemoembolization, RTx radiotherapy.